Log in

NASDAQ:RGLS - Regulus Therapeutics Stock Price, Forecast & News

$0.82
-0.01 (-1.20 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.81
Now: $0.82
$0.90
50-Day Range
$0.82
MA: $1.09
$1.50
52-Week Range
$0.50
Now: $0.82
$1.74
Volume96,657 shs
Average Volume121,798 shs
Market Capitalization$17.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RGLS
CUSIP75915K10
Phone858-202-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$70,000.00
Book Value($0.67) per share

Profitability

Net Income$-48,710,000.00
Net Margins-325.85%

Miscellaneous

Employees24
Market Cap$17.24 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.


Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) issued its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.00. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. View Regulus Therapeutics' Earnings History.

When is Regulus Therapeutics' next earnings date?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Regulus Therapeutics.

What price target have analysts set for RGLS?

4 analysts have issued 12-month price targets for Regulus Therapeutics' stock. Their forecasts range from $1.00 to $2.00. On average, they expect Regulus Therapeutics' share price to reach $1.50 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price. View Analyst Price Targets for Regulus Therapeutics.

What is the consensus analysts' recommendation for Regulus Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regulus Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regulus Therapeutics.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:
  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (2/18/2020)
  • 2. HC Wainwright analysts commented, "We have assessed Regulus Therapeutics using a discounted cash flow (DCF)-based approach, which ascribes value solely to the RGLS4326 program and the development-related milestone payments slated to be paid by Sanofi contingent upon continued progress with RG-012. Our assumptions include a 15% probability of regulatory approval for 20% probability of continued clinical advancement for RG-012. We also utilize a 15% discount rate, 0.5% terminal growth rate and 30% effective tax rate." (9/6/2019)

Has Regulus Therapeutics been receiving favorable news coverage?

News headlines about RGLS stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regulus Therapeutics earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Regulus Therapeutics.

Are investors shorting Regulus Therapeutics?

Regulus Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 654,800 shares, an increase of 35.8% from the January 15th total of 482,200 shares. Based on an average daily volume of 271,100 shares, the short-interest ratio is presently 2.4 days. Currently, 3.8% of the shares of the stock are short sold. View Regulus Therapeutics' Current Options Chain.

Who are some of Regulus Therapeutics' key competitors?

What other stocks do shareholders of Regulus Therapeutics own?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:
  • Mr. Joseph P. Hagan, Pres, CEO & Director (Age 50)
  • Mr. Daniel R. Chevallard, Chief Financial Officer (Age 38)
  • Mr. Christopher Ray Aker J.D., VP of Legal Affairs & Corp. Sec.
  • Mr. Turner Jenkins, Director & Head of Corp. Devel.

Who are Regulus Therapeutics' major shareholders?

Regulus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.27%) and Rockefeller Capital Management L.P. (0.52%). Company insiders that own Regulus Therapeutics stock include Christopher Ray Aker, Daniel R Chevallard, Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris and Stelios Papadopoulos. View Institutional Ownership Trends for Regulus Therapeutics.

Which institutional investors are buying Regulus Therapeutics stock?

RGLS stock was bought by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P. and Renaissance Technologies LLC. Company insiders that have bought Regulus Therapeutics stock in the last two years include Joseph P Hagan, Kathryn J Collier, Pascale Witz, Peter J Barris and Stelios Papadopoulos. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy shares of Regulus Therapeutics?

Shares of RGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of RGLS stock can currently be purchased for approximately $0.82.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $17.24 million and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-48,710,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis. Regulus Therapeutics employs 24 workers across the globe.View Additional Information About Regulus Therapeutics.

What is Regulus Therapeutics' official website?

The official website for Regulus Therapeutics is http://www.regulusrx.com/.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-202-6300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  441 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  751
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe RGLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel